We are live on ! Find out more
ASBPW

Aspire Biopharma Warrant
ASBPW

35 hedge funds and large institutions have $2.63M invested in Aspire Biopharma Warrant in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

3% less funds holding

Funds holding: 36 → 35 (-1)

42% less capital invested

Capital invested by funds: $4.53M → $2.63M (-$1.9M)

Holders
35
Holders Change
-1
Holders Change %
-2.78%
% of All Funds
0.56%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
3
Closed
1
Calls
$2.12M
Puts
–
Net Calls
+$2.12M
Net Calls Change
+$13K

Top Buyers

Rank Fund Capital Flow
1
CM
Cohanzick Management
New York
+$11K
2
SFM
Spartan Fund Management
Canada
+$9.42K
3
PC
Periscope Capital
Ontario, Canada
+$562
4
FSI
Flow State Investments
Illinois
+$327

Top Sellers

Rank Fund Capital Flow
1
CS
Clear Street
New York
-$6.42K
2
CH
CVI Holdings
Delaware
-$1.97K
3
AA
AQR Arbitrage
Connecticut
-$1.24K
4
MP
Mangrove Partners
Connecticut
-$139
Name Holding Trade Value Shares
Change 		Change in
Stake
LP
1
LMR Partners
United Kingdom
$1.31M – – –
MP
2
Mangrove Partners
Connecticut
$657K -$139 -2,100 -3%
AC
3
Athos Capital
Hong Kong
$262K – – –
PC
4
Periscope Capital
Ontario, Canada
$60.1K +$562 +8,500 +0.6%
SCM
5
Saba Capital Management
New York
$44.3K – – –
Adage Capital Partners
6
Adage Capital Partners
Massachusetts
$43.9K – – –
LA
7
Linden Advisors
New York
$40.5K – – –
AA
8
AQR Arbitrage
Connecticut
$27.2K -$1.24K -18,753 -3%
SC
9
Sculptor Capital
New York
$22.5K – – –
Verition Fund Management
10
Verition Fund Management
Connecticut
$18.1K – – –
WAM
11
Wolverine Asset Management
Illinois
$16.8K – – –
Barclays
12
Barclays
United Kingdom
$14.6K – – –
TCA
13
Taconic Capital Advisors
New York
$12.5K – – –
Balyasny Asset Management
14
Balyasny Asset Management
Illinois
$8.36K – – –
D.E. Shaw & Co
15
D.E. Shaw & Co
New York
$8.36K – – –
SFM
16
Spartan Fund Management
Canada
$7.82K +$9.42K +142,486 +320%
Nomura Holdings
17
Nomura Holdings
Japan
$7.5K – – –
RCM
18
Radcliffe Capital Management
Pennsylvania
$7.37K – – –
CCM
19
Context Capital Management
California
$7K – – –
CM
20
Cohanzick Management
New York
$6.97K +$11K +166,667 New
SRCM
21
Sage Rock Capital Management
New York
$6.69K – – –
PAMP
22
Polar Asset Management Partners
Ontario, Canada
$5.79K – – –
WA
23
Whitebox Advisors
Minnesota
$5.22K – – –
KL
24
KIM LLC
Kansas
$4.18K – – –
HCM
25
Highbridge Capital Management
New York
$4K – – –
1
2

ASBPW Hedge Fund Activity: Q1 2023 in Review

35 of the 6,277 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma Warrant (ASBPW) for Q1 2023, worth a combined $2.63M — down 42% from $4.53M a quarter earlier.

Fund positioning in ASBPW was balanced in Q1 2023: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 3 trimmed.

The largest buyer was Cohanzick Management, opening a new position worth an estimated $11K. The largest seller was Clear Street, cutting an estimated $6.42K.

  • 35 institutional investors held Aspire Biopharma Warrant (ASBPW) as of Q1 2023, down from 36 in Q4 2022.
  • Funds reported $2.63M of Aspire Biopharma Warrant stock for Q1 2023, down 42% quarter-over-quarter.
  • 1 fund opened new Aspire Biopharma Warrant positions in Q1 2023 and 1 closed out, a net change of 0 holders.
  • The largest Aspire Biopharma Warrant buyer in Q1 2023 was Cohanzick Management, an estimated $11K added.
  • The largest Aspire Biopharma Warrant seller in Q1 2023 was Clear Street, an estimated $6.42K sold.

Based on aggregated 13F filings for Q1 2023.